John Leonard, CFA
Special situations, micro-cap, contrarian, CFA

Columbia Laboratories Needs A Carl Icahn

Investment thesis

  • Columbia Laboratories (CBRX) trades at an attractive valuation due to an expected temporary drop in sales of its key product as well as fears of another expensive acquisition.
  • However this is more than reflected in the recent price decline and ignores the growing free cash flow, significant tax assets and attractive product development model.
  • Moreover, recent involvement by Carl Icahn in a larger women's healthcare company highlights the potential for another activist investor to maximize shareholder value.

Company overview

CBRX focuses on the reproductive healthcare market and recently entered the pharmaceutical development and analytical services market with the acquisition of Molecular Profiles.

The primary product is CRINONE, a sustained-release bioadhesive progesterone gel used to treat infertility and secondary...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details